TUMOR RESPONSE TO NEOADJUVANT LONG-COURSE CHEMORADIOTHERAPY DEPENDS ON THE RECTAL CANCER PATIENT GENDER
Velda Smajlbegović, Snježana Ramić, Iva Kirac, Meliha Solak Mekić, Loris Ćurt, Danko Velimir Vrdoljak · 2024
Read TUMOR RESPONSE TO NEOADJUVANT LONG-COURSE CHEMORADIOTHERAPY DEPENDS ON THE RECTAL CANCER PATIENT GENDER by Velda Smajlbegović, Snježana Ramić, Iva Kirac, Meliha Solak Mekić, Loris Ćurt, Danko Velimir Vrdoljak (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12520300.txt.
Description
Velda Smajlbegović and co-authors ask whether men and women with rectal cancer respond in the same way to combined drug and radiation treatment before surgery, in a 2024 study. They review 192 patients who had the long course of treatment, then surgery. Before treatment, the sexes differed only in obesity rates.
After treatment, women had more cancer left in nearby lymph nodes than men. Only 27 percent of women had a strong tumor shrink, against about 41 percent of men. Women also saw their disease return sooner, even when treatment seemed to clear the tumor. In men, leftover tumor depth and poor shrink marked earlier return as well, along with cut edges that still held cancer. The team raise the possibility that pre-surgery treatment should be tuned by sex.
Catalog record
| CREATOR | Velda Smajlbegović, Snježana Ramić, Iva Kirac, Meliha Solak Mekić, Loris Ćurt, Danko Velimir Vrdoljak |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |